window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Development

  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Development,Pharmaceuticals and therapeutics,Regulatory Affairs

    Symeres acquires DGr Pharma to enhance regulatory expertise and expand biopharma capabilities

    Symeres, a global contract research, development and manufacturing organization, has [...]

    September 10, 2025
  • Chronic diseases,Drug Development,European biotech,Pharmaceuticals and therapeutics

    MRM Health raises €55 million to advance microbiome-based therapies for ulcerative colitis and beyond

    MRM Health, a clinical stage biopharmaceutical company developing microbiome-based therapeutics, [...]

    September 9, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Technology and platforms

    Lilly launches $1 billion TuneLab AI platform to boost biotech drug discovery

    Eli Lilly and Company has launched TuneLab, a new artificial [...]

    September 10, 2025
  • Clinical Trials,Drug Development,European biotech,Precision medicine

    DeuterOncology presents phase 1 data for do-2 MET inhibitor showing tumour control with low side effects

    DeuterOncology, a clinical-stage biotech company developing deuterated cancer therapies, has [...]

    September 10, 2025
  • Drug Development,Oncology,Partnerships & Funding,Precision medicine,Research & Development

    New glioblastoma treatment project secures funding from The Brain Tumour Charity

    Medicines Discovery Catapult (MDC) and King’s College London (KCL) have [...]

    September 9, 2025
  • Chronic diseases,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics

    Skye completes 26-week CBeyond study of nimacimab and eyes 52-week weight loss data

    Skye Bioscience has reached a key milestone in its CBeyond [...]

    September 8, 2025
  • Drug Development,Movers & Shakers,Oncology,Rare Diseases,Regulatory Affairs

    Amorphical names Eden Ben CEO to drive regulatory strategy and expand nano-mineral therapeutics pipeline

    Amorphical has appointed Eden Ben as chief executive officer, as [...]

    September 10, 2025
  • Drug Development,RNA Therapeutics,Technology and platforms

    Hongene to supply exNA oligonucleotide technology under new licensing deal

    Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) [...]

    September 7, 2025
  • Artificial Intelligence,Biotech,Clinical Development,Data Management,Drug Development,Research & Development

    Biostate AI launches K-Dense beta to accelerate biological discovery from years to days

    Biostate AI has launched K-Dense Beta, a multi-agent AI system [...]

    September 22, 2025
  • Biologics & Biosimilars,Drug Development,Global health,Pharmaceuticals and therapeutics,Research & Development,Technology and platforms

    Cerium catalyst breakthrough could streamline greener drug development

    Japanese researchers discover a way to perform two different chemical [...]

    August 21, 2025
Previous121314Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno Scientific reports long-term safety data from CS1 pulmonary arterial hypertension program
    Categories: Cardiovascular diseases, Clinical Trials, Rare Diseases, Regulatory Affairs, Research & Development
  • City St George’s and Paradigm Biopharmaceuticals study osteoarthritis pain drug mechanism
    Categories: Clinical Trials, Neurosciences, Partnerships & Funding, Research & Development
  • BIOGRUND and Seprify launch plant-based tablet coating to replace titanium dioxide
    Categories: Ingredients, Manufacturing, Packaging, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top